|
ImmunoGen: Corporate Presentation (Immunogen) - Dec 12, 2015 - "Coltuximab Ravtansine – Notable Single-Agent Activity in Heavily Pre-treated Patients"; "Proof-of-concept achieved: 44% ORR (n=41) exceeded pre-set threshold
for success; 4 CRs, 14 PRs, 54% ORR – relapsed disease; (n=26), 27% ORR – refractory to last treatment (n=15), Median duration of response: 5.5 months; "Activity seen in hard-to-treat DLBCL patient populations: 21% ORR – primary refractory disease (n=14);1 CR, 2 PRs, Benefit in hard-to-treat recurrent GCB DLBCL comparable to recurrent ABC DLBCL"; "Favorable tolerability profile, few grade 3/4 adverse events"
P2 data • Non-Hodgkin's Lymphoma • Oncology
|